

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

B16-F1

RRID:CVCL_0158

Type: Cell Line

Proper Citation

BCRJ Cat# 0045, RRID:CVCL_0158

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0158

Proper Citation: BCRJ Cat# 0045, RRID:CVCL_0158

Description: Cell line B16-F1 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Male

Disease: Mouse melanoma

Defining Citation: [PMID:210294](#), [PMID:1109790](#), [PMID:6498800](#), [PMID:6539703](#), [PMID:11833741](#), [PMID:22797548](#), [PMID:25277546](#), [PMID:31220119](#), [PMID:33596583](#)

Comments: Karyotypic information: Near tetraploid karyotype (PubMed=33596583)., Characteristics: Has a low metastatic potential., Characteristics: Obtained from the pulmonary melanoma module of the 1st serial passage of the B16-F0 parent cell line in C57BL/6 mice.

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: B16-F1

Synonyms: B16/F1, B16 F1, B16F1

Cross References: BTO:BTO_0003853, CLO:CLO_0001793, CLO:CLO_0050764, EFO:EFO_0022821, MCCL:MCC:0000050, CLDB:cl337, CLDB:cl338, ATCC:CRL-6323, BCRC:60030, BCRJ:0045, BioSample:SAMN11397654, CCRID:1101MOU-PUMC000365, CCRID:4201MOU-CCTCC00039, CCTCC:GDC0039, ChEMBL-Cells:ChEMBL4295385, ChEMBL-Targets:ChEMBL4296402, CLS:400122, ECACC:92101203, KCLB:80007, Lonza:1278, NCI-DTP:B16F1, PRIDE:PXD018083, PubChem_Cell_line:CVCL_0158, RCB:RCB2649, TKG:TKG 0347, TOKU-E:581, Wikidata:Q54752433

ID: CVCL_0158

Vendor: BCRJ

Catalog Number: 0045

Hierarchy: cvcl_0604

Record Creation Time: 20220427T215231+0000

Record Last Update: 20260830T002309+0000

Ratings and Alerts

No rating or validation information has been found for B16-F1.

No alerts have been found for B16-F1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 497 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Nogués L, et al. (2026) NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation. The EMBO journal, 45(14), 4988.

Su X, et al. (2026) Targeted delivery and controlled release of deferasirox for melanoma therapy. iScience, 29(4), 115303.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. Cancer immunology research, 14(1), 122.

Liu S, et al. (2026) γ -hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. Cell, 189(6), 1701.

Komuro M, et al. (2025) Loss of Actrt1 in non-hematopoietic stroma suppresses pathological angiogenesis and tumor progression. Biochemical and biophysical research communications, 790, 152916.

Wannakul T, et al. (2025) Loss of fatty acid-binding protein 7 promotes B16F10 melanoma metastasis. Scientific reports, 15(1), 10495.

Qu K, et al. (2025) Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice. International immunopharmacology, 167, 115648.

Yu Y, et al. (2025) PTEN protein phosphatase activity regulates metastasis by targeting PKC?. *iScience*, 28(6), 112741.

Alicea Pauneto CDM, et al. (2025) Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4. *Immunity*.

Gu C, et al. (2025) An innovative engineered IL-10 monomer strengthens T cell-mediated anti-tumor responses through anti-PD-1 cis-delivery. *Cell reports. Medicine*, 102515.

Novak J, et al. (2025) The adaptor protein Miro1 modulates horizontal transfer of mitochondria in mouse melanoma models. *Cell reports*, 44(1), 115154.

Buracco S, et al. (2024) Scar/WAVE drives actin protrusions independently of its VCA domain using proline-rich domains. *Current biology : CB*, 34(19), 4436.

Huang YH, et al. (2024) Discovery of a mu-opioid receptor modulator that in combination with morphinan antagonists induces analgesia. *Cell chemical biology*.

Bugno J, et al. (2024) Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(19), 4450.

Trimaglio G, et al. (2024) The C-type lectin DCIR contributes to the immune response and pathogenesis of colorectal cancer. *Scientific reports*, 14(1), 7199.

Hernandez-Franco JF, et al. (2024) Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity. *NPJ vaccines*, 9(1), 149.

Hunt EG, et al. (2024) Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. *Cell metabolism*.

Gaeta IM, et al. (2023) BioID2 screening identifies KIAA1671 as an EPS8 proximal factor that marks sites of microvillus growth. *Molecular biology of the cell*, 34(4), ar31.

Dej-Adisai S, et al. (2023) In Vitro, In Vivo, and In Silico Analyses of Molecular Anti-Pigmentation Mechanisms of Selected Thai Rejuvenating Remedy and Bioactive Metabolites. *Molecules (Basel, Switzerland)*, 28(3).

Jesus ANB, et al. (2023) Increased Expression of the ?133p53? Isoform Enhances Brain Metastasis. *International journal of molecular sciences*, 24(2).